

DAFTAR PUSTAKA

- Åblad, B., Carlsson, E. and Ek, L., 1973. Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists. *Life Sciences*, Vol. 12 No. 3 PART 1, pp. 107–119.
- Agarwal, R., 2014. Hypertension in hemodialysis patients treated with atenolol or lisinopril: A randomized controlled trial. *Nephrology Dialysis Transplantation*, Vol. 29 No. 3, pp. 672–681.
- Ahmed, A., 2002. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: How concerned should we be by the rise in serum creatinine?. *Journal of the American Geriatrics Society*, Vol. 50 No. 7, pp. 1297–1300.
- Ahmed, A. and Dell'Italia, L. J., 2004. Use of beta-blockers in older adults with chronic heart failure. *American Journal of the Medical Sciences*. Elsevier Masson SAS, Vol. 328 No. 2, pp. 100–111.
- Anter, E., Jessup, M. and Callans, D. J., 2009. Atrial fibrillation and heart failure: Treatment considerations for a dual epidemic, *Circulation*, 119(18), pp. 2516–2525.
- Aronow, W. S., Ahn, C. and Kronzon, I., 1997. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction $\leq 40\%$ treated with diuretics plus angiot, *American Journal of Cardiology*, 80(2), pp. 207–209.
- Bain, A., 2018. Beta-blocker use in cardiovascular disease. *British Journal of Cardiac Nursing*, 13(10),.
- Barrett, A. M., 1973. A new type of cardioselective adrenoceptive

- blocking drug. *Proceedings of the*.
- Bristow, M. R., 2011. Treatment of chronic heart failure with β -adrenergic receptor antagonists: A convergence of receptor pharmacology and clinical cardiology. *Circulation Research*, 109(10), pp. 1176–1194.
- Brogden, R. N., 1977. Acebutolol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Hypertension, Angina Pectoris and Arrhythmia. *Drugs*, 29(6), pp. 321–348.
- C. Thomas, M., 2016. Type 2 Diabetes and Heart Failure: Challenges and Solutions', *Current Cardiology Reviews*, 12(3), pp. 249–255.
- Chadda, K., 1986. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. *Circulation*, 73(3), pp. 503–510.
- Corsonello, A., Pedone, C. and Incalzi, R., 2010. Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions. *Current Medicinal Chemistry*, 17(6), pp. 571–584.
- Dodson, J. A. and Chaudhry, S. I., 2012. Geriatric Conditions in Heart Failure. *Current Cardiovascular Risk Reports*, 6(5), pp. 404–410.
- Douglas S., L., 2009. Relation of Disease Etiology and Risk Factors To Heart Failure With Preserved or Reduced Ejection. *Circulation*, 119(24), pp. 3070–3077.
- Düngen, H. D., 2011. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: The CIBIS-ELD trial', *European Journal of Heart Failure*, 13(6), pp. 670–680.
- Edes, I., Gasior, Z. and Wita, K., 2005. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: Results of the ENECA study', *European Journal of Heart Failure*, 7(4), pp. 631–639.
- Flather, M. D., 2005. FASTTRACK Randomized trial to determine the

- effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS), *European Heart Journal*, 26(3), pp. 215–225
- Fongemie, J. and Felix-Getzik, E., 2015. A Review of Nebivolol Pharmacology and Clinical Evidence, *Drugs*. Springer International Publishing, 75(12), pp. 1349–1371.
- Ghio, S., 2006. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: Results of the SENIORS echocardiographic substudy, *European Heart Journal*, 27(5), pp. 562–568.
- Gibbs, C. R., Jackson, G. and Lip, G. Y. H., 2010. Non-drug management of chronic low back pain', *Evidence-Based Nursing*, 13(2), pp. 62–67.
- González, G., 1982. Pharmacokinetics of furosemide in patients with hepatic cirrhosis', *European Journal of Clinical Pharmacology*, 22(4), pp. 315–320.
- Hunt, S. A., 2005. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult - Summary article: A report of the American college of cardiology/American heart association task force on practice guidelines, *Journal of the American College of Cardiology*. Elsevier Masson SAS, 46(6), pp. 1116–1143.
- Inamdar, Arati and Inamdar, Ajinkya, 2016. Heart Failure: Diagnosis, Management and Utilization', *Journal of Clinical Medicine*, 5(7), p. 62.
- Jahan, N., 2016. How to Conduct a Systematic Review: A Narrative Literature Review, *Cureus*, (November).
- Jessup, M. and Brozena, S., 2003. Medical Progress Heart Failure, *The New England Journal of Medicine*, pp. 2007–2018.

- John, T., 2015. Acute decompensated heart failure, *Nihon rinsho. Japanese journal of clinical medicine*, 71(6), pp. 1035–1041.
- Kerr, D., 1990. Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects, *British Journal of Clinical Pharmacology*, 29(6), pp. 685–693.
- Kurmani, S. and Squire, I., 2017. Acute Heart Failure: Definition, Classification and Epidemiology, *Current Heart Failure Reports. Current Heart Failure Reports*, 14(5), pp. 385–392.
- Lakatta, E. G. and Levy, D., 2003. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises: Part I: Aging arteries: A “set up” for vascular disease, *Circulation*, 107(1), pp. 139–146.
- Lee, H. Y. and Baek, S. H., 2016. Optimal use of beta-blockers for congestive heart failure, *Circulation Journal*, 80(3), pp. 565–571.
- Marlin, G., 1975. An investigation into the cardiac and pulmonary beta-adrenoceptor blocking activity of ICI 66,082 in man., *British Journal of Clinical Pharmacology*, 2(2), pp. 151–157.
- McMurray, J. J. V., 2012. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart, *European heart journal*, 33(14), pp. 1787–1847.
- Nikhra, V., 2017. Aging Heart: Recent Research and Concepts, *Gerontology & Geriatrics Studies*, 1(1), pp. 1–11.
- Nobre, F., 2006. Antihypertensive Agents Have Different Ability to Modulate Arterial Pressure and Heart Rate Variability in 2K1C Rats, *American Journal of Hypertension*, 19(10), pp. 1079–1083.

- North, B. J. and Sinclair, D. A., 2012. The intersection between aging and cardiovascular disease, *Circulation Research*, 110(8), pp. 1097–1108.
- Palazzuoli, A., 2002. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure, *European Journal of Heart Failure*, 4(6), pp. 765–770.
- Palazzuoli, A., 2005. Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure, *Journal of Cardiovascular Pharmacology*, 45(6), pp. 563–568.
- Pine, M., 1975. Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris, *Circulation*, 52(5), pp. 886–893.
- Pitt, B., 2014. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction', *The New England Journal of Medicine*, 348(14), pp. 1309–1321.
- Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, John G.F., 2016. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure', *European Heart Journal*, 37(27), pp. 2129-2200m.
- Prihatiningsih, D. and Sudyasih, T., 2018. Perawatan Diri Pada Pasien Gagal Jantung', *Jurnal Pendidikan Keperawatan Indonesia*, Vol. 4(2).
- Ramani, G. V., Uber, P. A. and Mehra, M. R., 2010. Chronic heart failure: Contemporary diagnosis and management, *Mayo Clinic Proceedings*, 85(2), pp. 180–195.
- Reiter, M. J., 2004. Cardiovascular drug class specificity: β -blockers, *Progress in Cardiovascular Diseases*, 47(1), pp. 11–33.
- Reyes, E. B., 2016. Heart failure across Asia: Same healthcare burden but differences in organization of care, *International Journal of*

- Cardiology*. The Authors, 223, pp. 163–167.
- Rosella, F., 2015. Writing narrative literature reviews', *Medical Writing*, 24(4), pp. 230–235.
- Saczynski, J. S., 2009. Clinical features, treatment practices, and hospital and long-term outcomes of older patients hospitalized with decompensated heart failure: The Worcester heart failure study , *Journal of the American Geriatrics Society*, 57(9), pp. 1587–1594.
- Sessa, M., 2019. Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study', *Scientific Reports*. Springer US, 9(1).
- Siebert, D. C., Andre, H. and Thomas, N., 2007. Stereochemical Comparison of Nebivolol with other b-Blockers, 43(March 2010), pp. 103–109.
- Singh, B. N., 1975. A comparison of the actions of ICI66082 and propranolol on cardiac and peripheral β -adrenoceptors, *European Journal of Pharmacology*, 34(1), pp. 75–86.
- Stansfield, W. E., 2014. *The Pathophysiology of Cardiac Hypertrophy and Heart Failure, Cellular and Molecular Pathobiology of Cardiovascular Disease*. Elsevier.
- Tardif, J. C., 2005. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina, *European Heart Journal*, 26(23), pp. 2529–2536.
- do Vale, G. T., 2018. Three Generations of β -blockers: History, Class Differences and Clinical Applicability, *Current Hypertension Reviews*, 15(1), pp. 22–31.
- Velagaleti, R. S. and Vasan, R. S., 2007. Heart Failure in the Twenty-First Century: Is it a Coronary Artery Disease or Hypertension Problem?, *Cardiology Clinics*, 25(4), pp. 487–495.
- Van de Water, A., 1988. Pharmacological and Hemodynamic Profile on

Nebivolol, a Chemically Novel, Potent, and Selective B1-Adrenergic Antagonist, pp. 552–563.

Weber, M. A., 2014. Clinical Practice Guidelines for the Management of Hypertension in the Community: A Statement by the American Society of Hypertension and the International Society of Hypertension Clinical Practice Guidelines for the Management of Hypertension in the Comm, *Journal of Clinical Hypertension*, 16(1), pp. 14–26.

Yancy, C. W., 2013. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American college of cardiology foundation/American Heart Association task force on practice guidelines, *Circulation*, 128(16), pp. 1810–1852.

Zamora, S. G. and Parodi, R., 2011. Cough and angioedema in patients receiving angiotensin-converting enzyme inhibitors. Are they always attributable to medication?', *Revista Argentina de Cardiologia*, 79(2), pp. 157–163.

Zeitler, E. P. and Eapen, Z. J., 2015. Anticoagulation in heart failure: A review, *Journal of Atrial Fibrillation*, 8(1), pp. 31–38.